Article

Urologist Raoul Concepcion Explains Gleason Score and Gleason Grade

Raoul Concepcion, a urologist with Urology Associates in Nashville, Tenn., explains Gleason score and Gleason grade as it relates to a prostate cancer diagnosis.

Raoul Concepcion, a urologist with Urology Associates in Nashville, Tenn., explains Gleason score and Gleason grade as it relates to a prostate cancer diagnosis. Features that define prostate cancer fall under Gleason grade and score. Gleason grade ranges from 1 to 5, where 5 is considered most aggressive.

Prostate cancer can be heterogeneous, so in the same biopsy, the sample may show different grades, or patterns. The Gleason score is the sum of the two most common patterns. For example, a biopsy may reveal a Gleason grade of 4 as the most prevalent pattern, with 3 as the second. The Gleason score would be a 7.

"A lot of people will say 'I have a Gleason 7 score.' I personally tend to stay away from the summation only because if you think about a 7, there are a number of different ways you can get to a 7 with a grading scale of one through five," he says. "It could be a 3 plus 4... or a 2 plus 5."

With the first number being the most prominent, urologists may treat according to the more dominant pattern than simply the Gleason score.

"If you have one patient with a Gleason 3 plus 4 and another patient with a 4 plus 3, they are both 7s, but we actually look at those patients very differently," he says."The 4 plus 3 is at a much higher risk than the gentleman with a 3 plus 4."

Related Videos
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Dr. Anna Arthur is the Director of the Medical Nutrition Science Program, as well as a tenure-track Assistant Professor in the Department of Dietetics and Nutrition at the University of Kansas Medical Center.
Dr. Ritu Salani, the Director of Gynecologic Oncology at the University of California, Los Angeles (UCLA), UCLA Health, and a board-certified gynecologic oncologist.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Related Content